Specific Properties of the Drugs Produced by Dna Recombinant Biotechnology
DOI:
https://doi.org/10.5644/Radovi.310Abstract
Products produced by DNA recombinant biotechnology processes may be considered a new possibility in the field of therapy. In the period from 1985 to 1989 the following recombinant DNA drugs were approved: human insulin, human growth hormones, interferon alpha 2a and 2b, interleukin 2, alteplase, muromanab CD 3, erythropoietin and hepatitis B vaccine. Many new products are being developed. Since a number of peptides and proteins are rapidly destroyed in the body, new formulations and systems have been developed in order to increase the steady drug concentration in blood circulation or locally at the site of application, further, to increase the efficacy of drugs and to minimize the incidence and severity of adverse side effects. The proteins and peptides are unable to reach secluded organs or sites where the therapeutic effect is desirable, therefore more selective routes of administration than the venous one is being introduced. The cost of some biological drugs may result in their limited use, thus guidelines for a proper administration have been issued.
References
Esber, E. C.: United States Perspectivies on the Evaluation of Therapeutic Biological Products. V: Therapeutic Peptides and Proteins (Marshak, D. i Liu, D. eds.). Cold Spring Harbor Laboratory, New York 1989, pp. 201—206.
Hayakawa, T.: Current Regulaltory Situation in Japan tvith Respect to the Quality of Therapeutic Peptides and Proteins. V: Therapeutic peptides and proteins (Marshak, D. i Liu, D. eds.). Cold Spring Harbor Laboratory, New York 1989, pp. 195—200.
Taguchi, T.: Phase I Study of Recombinat Human Tumor Necrosis Factor (rhTNF: PT-050). Cancer Dct Prev 12, 561—572, 1988.
Van Brunt, J.: Lymphokine Receptors as Therapeutics, Biotechnology, 668—669, 1989.
Wong, G. H. W. i Goeddel, D. V.: Biological Activities and Production of TNF Alfa. V: Monokine and other non-lymphocytic cytokines (MC Pawanda et al.). Alan R. Liss Ine., New York 1988, pp. 251—260.
Reynolds, J. E. F.: Interferons. V: Martindale the Extra Pharmacopoja, 29. Edition. The Pharmaceutical Press, London 1989, pp. 696—699.
Tsujimoto, M., Tanaka, S., Sakuragawa, Y. et al.: Comparative Studies of the Biological Activities of Human Tumor Necrosis Factor and its Derivatives. J. Biochem 101, 919—925, 1987.
Doyle, M. V., DeGroat, S., Lowitz, R. et al.: In Vivo Activation of Cytolitic Cell Activity During Recombinant IL 2—125 Clinical Trials in Cancer Patients. V: Immune regulation by characterized polypeptides (Goldstein, G., Bach, J. F. i Wigzell, H. eds.), Alan R. Liss Ine., New York 1987, pp. 353—362.
Clark-Lewis, I., Aebersold, R., Ziltener, H. et al.: Structure-Function Studies of Interleukin 3 Using an Automated Peptide Synthesis Approach. V: Immune regulation by characterized polypeptides (Goldstein,
G., Bach, J. F. i Wiozell, H. eds.). Alan R. Liss Ine., Nev York, 1987, pp. 323—334.
Sreekrishna, S., Potenz, R. H. B., Cruze, J. A. et al.: High Level Expression of Heterologous Proteins in Methlotrophic Yeast Pichia Pastoris. J Basic Microbiol 28, 265—278, 1988.
Goldstein, G. M. P., Scheid, E. A., Boyse, M. P., Schlesinger, D. H. i VVaurve, Van J.: A Synthetic Bentapeptide with Biological Activitv Characteristic of the Thymic Hormone Thymopoetin. Science 204, 1309—1310, 1979.
Chipens, G.: New Biologically Active Fragments of Immunoglobulins. Adv. Drug Delivery Rev 2, 167—206, 1988.
Evans, B. E.: Recent Development in Cholecystokinin Antagonist Research. Drugs of the Future 14, 971—979, 1989.
Bocei, V..- Catabolism of Therapeutic Proteins and Peptides with implications for Drug Delivery. Adv Drug Rev 4, 149—169, 1990.
Taguchi, T., Kimoto, Y. i Tanji, Y.: Clinical Studies of Recombinant human Tumor Mecrosis Factor. V: Tumor Necrosis factor/Cachectin and Related Cytokines (B. Bonavida, G. E. Gifford, iH. Kirchner, L. J. Old eds.).
Karger, Basel 1988, pp. 196—204.
Naito, K., Pellis, N. R. i Kahan, B. D.: Effect of Continuous Administiration of Inerleukin 2 on Active Specific Chemoimmunotherapy with Extracted Tumor-Specific Transplantation Antigen and Cyclophospamide. Cancer Res 48, 101—108, 1988.
Amkraut, A., Eckenhoff, J. B. i Nichols, K.: Osmotic Delivery of Peptides and Macromolecules. Adv Drug Rev 4, 255—276, 1990.
Bubenik, J.: Local Immunotherapy of Cancer with Interleukin 2. Immunol Lett 21, 267—276, 1989.
Takenaka, H., Fujioka, K. i Takada, Y.: New Formulations of interferon. V: Therapeutic peptides and protein (D. Marshak i D. Liu eds.). Cold Spring Harbor Laboratory, New York 1989, pp. 37—40.
Katre, N. V., Young, S. D. i Zimmerman, R.: Chemical Modification of Interleukin 2 with Polymers: a Patent Drug Delivery System. V: Therapeutic Peptides and Proteins (D. Marshak i £>. Liu eds.). Cold Spring Harbor Laboratory, New York 1989, pp. 173—177.
Muranishi, S. i Takada, K.: Biopharmaceutical Aspects on Enhanced Transmembrane Delivery of Peptides and Proteins. V: Therapeutic peptides and proteins (D. Marshak i D. Liu eds.). Cold Spring Harbor Laboratory, New York 1989, pp 47—50.
Illum, L.: Nasal Delivery of peptide and Protein Drugs. V: Therapeutic Peptides and Proteins (D. Marshak i D. Liu eds.). Cold Spring Harbor Laboratory, New York 1989, pp. 51—57.
Daugherty, A. L., Liggitt, D., McCabe, J. C., Moor, J. A. i Paton, J. S.: Absorption of Recombinant Methionyl-Human Grovvth Hormone (Meth-GH) From Rat Nesal Mucosa. Int J Pharm 45, 197—202, 1988.
Stale, A.: Razvoj novih oblik zdravih Proteus 50, 184—187, 1988.
Štale, A.: Liposomi — nova potencialna oblika zdravih Farm vestnik 31, 197—202, 1980.
Duezguenes, N., Perumal, V. K., Brunett, E. N., Gangadhuram, P. R. J. i Debs, R. J.: Treatment of Mycobacterium Avium Complex Infections by free and Liposome-Encapsulated Tumor Necrosis Factor Alpha (cachectin): Studies on Peritoneal Macrophages and the Beige Mouse Model. V: Liposomes in the therapy of infectious diseases and cancer (G. Lopez--Bemstein, I. J. Fidler eds.). Alan R. Liss Ine., New York 1989, pp. 287—294.
Reed, S. G.: Liposome-Encapsulated Lymphokine for the Treatment of Experimental Visceral Lishmaniasis. V: Liposomes as drug carriers (G. Gregoriadis ed.). John Wiley & Sons, Chichester 1988, pp. 337—344.
Sajki, I. i Fidler, L. J.: Synergistic Activation by Recombinant Mouse Interferon Gama and Muramyl Dipeptide of Tumoricidal Properties in Mouse Macrophages. J Immunol 135, 684—688, 1985.
Orr, D. W., Lewis, M. i Oldham, R. K.: Cancer Biotherapy: 1987 Disease-Related Activity. V: Principies of cancer biotherapy (R. K. Oldham ed.). Raven Press, New York 1987, pp. 469—487.
Chien, Y. W. i Wearley, L. L.: Aids and Chemotherapy. Drugs of Today 25, 19—25, 1989.
Anon: Interleukin Futures. Biotechnology 7, 661—667, 1989.
Anon.: Erythropoetin Reaches the Pharmacy. Lancet 2, 1252—1254, 1989.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Anton Štalc
This work is licensed under a Creative Commons Attribution 4.0 International License.
